(Q41673368)

6 October 2017

1 reference

title

Glutamate in schizophrenia: clinical and research implications (English)

1 reference

6 October 2017

1 reference

D C Goff

1

1 reference

6 October 2017

L Wine

series ordinal

2

1 reference

6 October 2017

language of work or name

English

0 references

publication date

1 October 1997

1 reference

6 October 2017

published in

Schizophrenia Research

1 reference

6 October 2017

volume

27

1 reference

6 October 2017

issue

2-3

1 reference

6 October 2017

page(s)

157-168

1 reference

Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's disease and schizophrenia

6 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

The association among negative symptoms, movement disorders, and frontal lobe psychological deficits in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Glutamate neurotoxicity and diseases of the nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Regional patterns of cholinergic and glutamate activity in the developing and aging human brain

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

The glutamatergic dysfunction hypothesis for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Oxidative stress, glutamate, and neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Cyloserine as an antidepressant agent

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Mesolimbic and mesocortical dopamine activation induced by phencyclidine: contrasting pattern to striatal response

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Effect on memory processing by D-cycloserine, an agonist of the NMDA/glycine receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Glutamate in schizophrenics and healthy controls

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Tardive dyskinesia and substrates of energy metabolism in CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

D-cycloserine added to clozapine for patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

NMDA-dependent modulation of CA1 local circuit inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic rodents

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Decreased hippocampal expression of a glutamate receptor gene in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Evidence for involvement of N-methyl-D-aspartate receptor in tonic inhibitory control of dopaminergic transmission in rat medial frontal cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Competitive antagonists and partial agonists at the glycine modulatory site of the mouse N-methyl-D-aspartate receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Cloned glutamate receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Glutamate receptor channels in rat DRG neurons: activation by kainate and quisqualate and blockade of desensitization by Con A

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Cellular and synaptic localization of NMDA and non-NMDA receptor subunits in neocortex: organizational features related to cortical circuitry, function and disease

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Dopamine release in the nucleus caudatus and in the nucleus accumbens is under glutamatergic control through non-NMDA receptors: a study in freely-moving rats

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Recent advances in the phencyclidine model of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Amelioration of negative symptoms in schizophrenia by glycine.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Glutamate receptors, microtubule associated proteins and developmental anomaly in schizophrenia: an hypothesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

The Schedule for the Deficit syndrome: an instrument for research in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Modulation of neuronal migration by NMDA receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Cerebrospinal fluid amino acid concentrations in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Glutamatergic control of dopamine release in the rat striatum: evidence for presynaptic N-methyl-D-aspartate receptors on dopaminergic nerve terminals.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Amino acid patterns in schizophrenia: Some new findings

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Physiological and pathophysiological roles of excitatory amino acids during central nervous system development

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

D-cycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Localization of dopamine D4 receptors in GABAergic neurons of the primate brain

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Magnesium gates glutamate-activated channels in mouse central neurones

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Glutamate receptor dysfunction and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Effects of dopamine D1 and D2 receptor blockade on MK-801-induced hyperlocomotion in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Metabotropic Glutamate Receptor Activation Produces Extrapyramidal Motor System Activation That Is Mediated by Striatal Dopamine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Mitochondrial dysfunction is a primary event in glutamate neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

The TiPS/TINS lecture: the molecular biology of mammalian glutamate receptor channels

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Low-concentration N-acetylaspartylglutamate suppresses the climbing fiber response of Purkinje cells in guinea pig cerebellar slices and the responses to excitatory amino acids of Xenopus laevis oocytes injected with cerebellar mRNA

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

d-Cycloserine therapy of psychosis by symptom provocation

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Electrical stimulation of the prefrontal cortex increases dopamine release in the nucleus accumbens of the rat: modulation by metabotropic glutamate receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Excitatory amino acids: implications for psychiatric disorders research

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Elevation of cerebral levels of nonessential amino acids in vivo by administration of large doses

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Glutamate receptor desensitization and its role in synaptic transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Abnormal excitatory neurotransmitter metabolism in schizophrenic brains

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Excitatory amino acid receptors in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Cognitive dysfunction in schizophrenia: organic vulnerability factor or state marker for tardive dyskinesia?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Presynaptic glutamate receptors modulate dopamine release from striatal synaptosomes

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Glycine therapy of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

A connectionist approach to the prefrontal cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900079-0

7 January 2021

10.1016/S0920-9964(97)00079-0

Identifiers

DOI

1 reference

6 October 2017

1 reference